InterMune to pay $36.9 million to settle off-label promotion charges

Share this article:
InterMune has agreed to pay federal and state governments more than $36.9 million to settle charges it illegally promoted its immune systems disorder drug Actimmune. The federal government charged the biotech firm with the off-label promotion of Actimmune to treat lung scarring caused by a condition known as idiopathic pulmonary fibrosis. As a result, InterMune knowingly caused the submission of fraudulent claims for reimbursement, US Justice Department officials said. InterMune will pay $30.2 million for losses suffered by the federal portion of the Medicaid program, the Medicare programs, the Veteran’s Administration and Federal Employees Health Benefits program. Under separate civil settlement agreements, the company will also pay nearly $6.7 million to state Medicaid programs. InterMune is expected to enter into an agreement with the federal government to defer prosecution for two years, contingent upon InterMune’s past and future cooperation in the investigation and efforts to implement changes to its compliance policies. The settlement followed a two-year investigation conducted by the federal government into the promotion of Actimmune. In March 2004, a former InterMune sales rep filed a wrongful termination suit against InterMune. The rep alleged that InterMune required the sales force to market Actimmune for unapproved indications and structured compensation systems based on unlawful marketing.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...